Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 257-264

  Alberti, P ^a   Rossi, E ^a   Cornblath, D R ^b   Merkies, I S J ^c,d   Postma, T J ^e   Frigeni, B ^a   Bruna, J ^f   Velasco, R ^f   Argyriou, A A ^g   Kalofonos, H P ^g   Psimaras, D ^h   Ricard, D ⁱ   Pace, A ^j   Galie E ^j   Briani, C ^k   Dalla Torre, C ^k   Faber, C G ^d   Lalisang, R I ^l   Boogerd, W ^m   Brandsma, D ^m   Koeppen, S ⁿ   Hense, J ⁿ   Storey, D ^o   Kerrigan, S ^o   Schenone, A ^p   Fabbri, S ^p   Valsecchi, M G ^a   Cavaletti, G ^a   more..

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Infection and Immunology   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ University of Paris Descartes   (France)

^j REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l MAASTRICHT UNIVERSITY   (Netherlands)

^m NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o WESTERN GENERAL HOSPITAL   (United Kingdom)

^p UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED SENSORY PERIPHERAL NEUROTOXICITY; COHORT ANALYSIS; HUMAN; INFLAMMATORY NEUROPATHY CAUSE AND TREATMENT SENSORY SUMSCORE; MAJOR CLINICAL STUDY; NATIONAL CANCER INSTITUTE COMMON TOXICITY CRITERIA SENSORY SCALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; TOTAL NEUROPATHY SCORE;

ASSESSMENT; CHEMOTHERAPY; NEUROPATHY; NEUROTOXICITY; PATIENT-REPORTED OUTCOME MEASURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME;

EID: 84894342495     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt409     Document Type: Article

References (20)

1. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14(Suppl 4): 445-454.
2. Frigeni B, Piatti M, Lanzani F et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011; 16: 228-236.
3. Cavaletti G, Frigeni B, Lanzani F et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46: 479-494.
4. Cavaletti G, Frigeni B, Lanzani F et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007; 12: 210-215.
5. Cavaletti G, Bogliun G, Marzorati L et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61: 1297-1300.
6. Cornblath DR, Chaudhry V, Carter K et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53: 1660-1664.
7. Merkies IS, Schmitz PI. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2006; 77: 970-972.
8. Cavaletti G, Cornblath DR, Merkies IS et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24: 454-462.
9. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
10. Hershman DL, Weimer LH, Wang A et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011; 125: 767-774.
11. Bennett BK, Park SB, Lin CS et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 2012; 20: 2959-2967.
12. Inoue N, Ishida H, Sano M et al. Discrepancy between the NCI-CTCAE and DEBNTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 2012; 17: 341-347.
13. Martina IS, van Koningsveld R, Schmitz PI et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 1998; 65: 743-747.
14. van Nes SI, Faber CG, Hamers RM et al. Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies. J Neurol Neurosurg Psychiatry 2008; 79: 832-834.
15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
16. Luckett T, King MT, Butow PN et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 2011; 22: 2179-2190.
17. Postma TJ, Aaronson NK, Heimans JJ et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41: 1135-1139.
18. Wolf SL, Barton DL, Qin R et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 2011; 20: 625-632.
19. Lavoie Smith EM, Barton DL, Qin R et al. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 2013; [Epub ahead of print].
20. Postma TJ. Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? Ann Oncol 2013; 24: 1424-1426.